Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim

Schizophrenia Bulletin

Volumn 32, Issue 2, 2006, Pages 220-222

  Laughren, Thomas ^a   Levin, Robert ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug development; Negative symptoms; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; ZIPRASIDONE;

ADD ON THERAPY; AGITATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG DESIGN; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; HUMAN; NEGATIVE SYNDROME; POPULATION RESEARCH; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33645221984     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbi039     Document Type: Conference Paper

References (6)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington D.C.: American Psychiatric Press; 1994.
2. Buchanan RW, David M, Goff G, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bull. 2005;31(1):1-15.
3. Laughren T. A regulatory perspective on psychiatric syndromes in Alzheimer disease. Am J Geriat Psychiat. 2001;9(4):340-345.
4. Laughren TP. Comorbid mood disorders and medical illness: a Food and Drug Administration perspective. Biol Psychiat. 2003;53:195-199.
5. Kirkpatrick B, Fenton W, Carpenter WT, Marder SR. Consensus statement on negative symptoms in schizophrenia. Schizophrenia Bull. in press.
6. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiat. 1982;39:784-788.